Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Atlas Venture is a biotechnology venture capital firm founded in 1993 and based in Cambridge, Massachusetts. The firm has established itself as a leader in seed-led venture creation, focusing on breakthrough biotech companies. Over its 30-year history, Atlas has developed a strong reputation for translating high-impact scientific research into viable medical solutions.
Currently, Atlas Venture operates with a team of experienced professionals and manages a significant amount of assets under management (AUM). The firm primarily invests in early-stage biotech companies, emphasizing collaboration with scientists and entrepreneurs. Their office is located at 300 Technology Square, 8th Floor, Cambridge, MA 02139, USA.
Atlas Venture specializes in the biotechnology sector, particularly in seed and Series A stages. The firm invests between $2 million and $15 million in early-stage companies that are focused on translating high-impact science into medicines. Their investment strategy is characterized by a collaborative, science-first approach, which allows them to work closely with life science entrepreneurs.
The firm targets sectors such as gene therapy, precision oncology, and RNA-modifying proteins. Atlas Venture seeks to partner with exceptional scientists and entrepreneurs who are committed to developing scalable biotech businesses. Their investment thesis emphasizes patient-centric drug development, ensuring that the innovations they support have a meaningful impact on healthcare.
Atlas Venture maintains a focused portfolio of biotech companies that exemplify their seed-led venture creation approach. Notable portfolio companies include:
This portfolio reflects Atlas Venture's commitment to advancing biotech innovations that address significant medical needs.
Bruce Booth: Partner at Atlas Venture, Bruce has extensive experience in the biotech sector. He has been involved in numerous successful investments and has a strong background in translating scientific research into commercial opportunities.
To pitch Atlas Venture, founders should use the contact form on their website or email them directly at atlasventure@atlasventure.com. It is important to include a comprehensive overview of the startup, the scientific innovation, and the potential market impact in the pitch deck.
On December 1, 2025, Atlas Venture made its latest investment, continuing its active engagement in the biotech sector. Over the past year, the firm has completed a total of 8 investments, reflecting its commitment to supporting early-stage biotech companies.
What are Atlas Venture's investment criteria?
Atlas Venture invests in early-stage biotech companies, specifically at the seed and Series A stages. They focus on companies that translate high-impact scientific research into medicines, particularly in sectors like gene therapy and precision oncology.
How can I apply or pitch to Atlas Venture?
Founders can pitch to Atlas Venture through their website at atlasventure.com/contact-us or via email at atlasventure@atlasventure.com. They recommend including a clear overview of the scientific innovation and its potential impact on healthcare.
What makes Atlas Venture different from other VC firms?
Atlas Venture emphasizes a hands-on approach to venture creation, working closely with scientists and entrepreneurs to build scalable biotech businesses. Their deep expertise in the biotech sector and collaborative model set them apart.
What is the geographic scope of Atlas Venture's investments?
Atlas Venture primarily invests in North America, with a strong focus on the biotech ecosystem in Cambridge, Massachusetts.
What is the typical check size for investments?
Atlas Venture typically invests between $2 million and $15 million in their portfolio companies, focusing on early-stage funding.
What kind of post-investment involvement does Atlas Venture have?
Atlas Venture is actively involved in the companies they invest in, providing operational support and strategic guidance to help translate scientific advancements into viable medical solutions.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.